Related Experiment Video
Updated: Jun 19, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Variegate porphyria in a 46-year-old patient taking sibutramine for weight loss
M Reiser1, S Eickmann, T Haverkamp
1Department of Medicine and Gastroenterology, Klinikum Vest GmbH - Paracelsus-Klinik Marl, Marl, Germany. m.reiser@paracelsus-klinik-marl.de
Abstract:
The acute hepatic porphyrias can cause life-threatening attacks of neurovisceral symptoms that mimic other acute medical conditions. Variegate porphyria caused by mutations in the protoporphyrinogen oxidase (PPOX) gene is a latent disorder characterized by exacerbations induced by fasting, alcohol consumption or certain drugs. We describe the case of a 46-year-old female patient presenting with a first episode of symptomatic porphyria after 10 d of sibutramine treatment for weight loss. Genetic analysis showed a heterozygous R168H hot spot mutation in the PPOX gene. A putative effect of sibutramine on the hepatic haem biosynthetic pathway and reduced food intake have likely caused this exacerbation of a porphyria attack. Although this may be the first case report of this kind, the risk of acute porphyria should be considered in patients using pharmacotherapy for obesity.
Related Concept Videos
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Antidepressant Drugs: MAOIs and Other Agents
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug Dosing: Obese Patients
Drug toxicity: Idiosyncratic Reactions
